MEDI5752 in Combination With Carboplatin Plus Pemetrexed in Unresectable Pleural Mesothelioma

Key Who May Qualify: - Participant must be ≥ 18 years at the time of screening - Histologically proven diagnosis of pleural mesothelioma with known histology (epithelioid vs. non-epithelioid) - Advanced unresectable disease that cannot be treated with curative surgery (with or without chemotherapy) - WHO/You should be able to carry out daily activities with 0 level of ability (ECOG 0) or 1 with no deterioration (that is, ECOG PS\>1) over the previous 2 weeks prior to day of first dosing - Has measurable disease per modified RECIST1.1 - Has adequate bone marrow reserve and organ function at baseline Key Who Should NOT Join This Trial: - As judged by the investigator, any condition that would interfere with evaluation of the investigational product or interpretation of participant safety or study results. - Active or prior documented autoimmune or inflammatory disorders - History of another primary malignancy with exceptions. - Uncontrolled intercurrent illness - Tuberculosis, hepatitis B (HBV) or hepatitis C (HCV), human weakened immune system virus (HIV) infection that is not well controlled - Any concurrent chemotherapy, radiotherapy, investigational, biologic, or hormonal therapy for cancer treatment - Untreated or progressive CNS metastatic disease Always talk to your doctor about whether this trial is right for you.